Home
Billing codes
J1427

PAYER POLICY CHANGES

J1427 Insurance Policy Changes

HCPCS J1427 is officially defined as "Injection, viltolarsen, 10 mg." HCPCS J1427 is referenced in 10 tracked payer policy changes from Florida Blue, Mississippi Medicaid (DOM), and 4 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J1427 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Florida Blue · Effective Jun 1, 2026High impact
New Drug Waste Reduction Guideline
Florida Blue, in collaboration with Prime Therapeutics Medical Pharmacy Solutions, began a Drug Waste Reduction Guideline for select provider-administered medications on June 1, 2026. Under the guideline, the medication dose must align to the most efficient vial size combination when clinically appropriate, and it applies to all Florida Blue and Truli for Health commercial plans. For prior authorization requests on listed medications, the optimized dose cannot be bypassed, and the request moves to pending status for additional clinical review.
Florida Blue · Effective Mar 1, 2026High impact
Notice of Change for Physician-Administered Drug Program
Florida Blue is expanding their Physician-Administered Drug Program (PADP) effective March 1, 2026, requiring preservice reviews for 25 specific specialty drug codes before administration. Claims will be denied without prior authorization, and providers cannot bill patients for denied charges.
Mississippi Medicaid (DOM) · Effective Jul 1, 2025Medium impact
Physician Administered Drugs: Prior Authorization Requirements
Effective July 1, 2025, Mississippi Medicaid will require prior authorization for 10 new physician-administered drugs (PADs) including aflibercept, olanzapine long-acting, risperidone, inclisiran, vutrisiran, patisiran, eptinezumab, viltolarsen, tezepelumab, and crizanlizumab. Additionally, pemetrexed (J9305) will no longer require prior authorization. Telligen handles all authorization requests for FFS Medicaid beneficiaries.
Aetna · Identified Aug 16, 2026Medium impact
Lyme Disease and other Tick-Borne Diseases (CPB 0215, reviewed 2026-07-21)
Aetna considers outpatient IV antibiotic therapy medically necessary for Lyme disease only when the clinical presentation is compatible with the disease and supported by two-tier serologic testing. Once Lyme disease is definitively diagnosed, an initial 4-week course of outpatient IV antibiotic therapy is medically necessary for persistent Lyme arthritis after failing a 4-week course of oral antibiotics, for moderate-to-severe cardiac or neurologic involvement, and for specified cases in pregnant women, and one repeat 4-week course is medically necessary with objective evidence of relapse, progression of organ damage, or a new focus or type of organ damage. Aetna considers IV antibiotic therapy for early Lyme disease, additional antibiotic therapy for post-treatment persistently fatigued patients, and a range of listed tests and treatments experimental, investigational, or unproven.
Aetna · Identified Aug 15, 2026Medium impact
Gene-Based Therapy for Duchenne Muscular Dystrophy (DMD) (CPB 0911, reviewed 2026-08-05)
Aetna's commercial policy requires precertification for casimersen (Amondys 45), delandistrogene moxeparvovec-rokl (Elevidys), eteplirsen (Exondys 51), golodirsen (Vyondys 53) and viltolarsen (Viltepso), and sets initial and continuation criteria for each. On November 14, 2025, the FDA approved new Elevidys labeling that adds a Boxed Warning for serious liver injury and acute liver failure, limits use to ambulatory patients aged four and older with a confirmed DMD gene mutation, and removes the indication for non-ambulatory patients.
Michigan Medicaid - MDHHS · Identified Jun 20, 2026Medium impact
MSA 21-18
MDHHS added, discontinued and re-covered several HCPCS and CPT codes in the July 2021 update to the Medicaid Provider Manual, with dates ranging from February 9, 2021 to April 16, 2021. Prior authorization was discontinued for 81510, 81511 and 81512 effective March 31, 2021, and coverage for M0239 and Q0239 was discontinued effective April 16, 2021 after the FDA revoked emergency use authorization for those codes. The update also set billing rules for MOMS claims, dental incomplete procedures, orthodontic treatment, diagnosis reporting and portable x-ray transportation.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
State and School Employees' Health Insurance Plan - Duchenne Muscular Dystrophy (DMD)
Elevidys (delandistrogene moxeparvovec-rokl) may be considered medically necessary as a single-dose intravenous infusion for Duchenne muscular dystrophy (DMD) when all listed criteria are met. Amondys 45 (casimersen), Exondys 51 (eteplirsen), Viltepso (viltolarsen), and Vyondys 53 (golodirsen) are considered investigational for DMD because there is insufficient evidence of clinical benefit. The most recent review, dated 02/24/2026, updated the Elevidys description to remove the non-ambulatory indication.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Duchenne Muscular Dystrophy (DMD)
Amondys 45 (casimersen), Exondys 51 (eteplirsen), Viltepso (viltolarsen), and Vyondys 53 (golodirsen) are considered investigational for the treatment of Duchenne muscular dystrophy because there is insufficient evidence of clinical benefit. Elevidys (delandistrogene moxeparvovec-rokl) is considered not medically necessary for DMD in ambulatory individuals who have a confirmed DMD gene mutation, as there is insufficient evidence to demonstrate clinical efficacy. The 02/24/2026 review removed the investigational statement for Elevidys in non-ambulatory individuals.
Colorado Medicaid · Identified Jun 20, 2026Medium impact
Health First Colorado (Colorado's Medicaid Program) News and Updates (B2200487 - 12/2022)
Effective December 1, 2022, breast pumps can be prescribed by certified nurse midwives as well as physicians, physician assistants and nurse practitioners, and HCPCS codes L8614 (cochlear device) and 31599 (gender-affirming surgeries) require prior authorization requests. Effective for dates of service on or after January 1, 2023, fingertip pulse oximeters billed under E0445 use modifier U1 and tabletop pulse oximeters use modifier U2, with U2 rates the same as the current E0445 rate. Effective January 1, 2023, a select group of additional physician-administered drugs, including Simponi, Stelara, Orencia, Tezspire, Oxlumo and three Duchenne muscular dystrophy drugs, are subject to prior authorization.
Colorado Medicaid · Identified Jun 20, 2026Medium impact
Health First Colorado (Colorado's Medicaid Program) News and Updates (B2300488 - 01/2023)
Effective January 1, 2023, claims billed with HCPCS 2023 procedure codes may begin suspending for EOB 0000, and claims will be released once the Colorado interChange update is complete. Effective January 1, 2023, a select group of additional physician-administered drugs require prior authorization, and prior authorization for CPT 92526 is no longer required when billed with CPT 74230 and 92611, while the multi-user breast pump rate for E0604 with modifier RR is $219.67. Depression screen claims using G8431 or G8510 must include U modifiers beginning July 1, 2023, after that requirement was postponed again, and claims without modifiers will be denied.

Watch J1427

Get one email when a payer policy names J1427, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

REFERENCE DATA

Payers with rules18

Payers requiring prior auth18

Aetna · Effective November 1, 2026
Prior authorization required
Participating provider precertification list for Aetna
Anthem BCBS · Effective November 1, 2026
Prior authorization required
Anthem Local PPO Precertification/Prior Authorization List (California | Anthem Blue Cross | Commercial)
Fidelis Care · Effective November 1, 2026
Prior authorization required
Fidelis Care Metal-Level Products authorization grid

FREQUENTLY ASKED QUESTIONS

Does Aetna require prior authorization for J1427?

Aetna lists J1427 on Participating provider precertification list for Aetna for commercial plans (list dated November 1, 2026). Verify with the payer before scheduling.

Does Ambetter require prior authorization for J1427?

Ambetter lists J1427 on Ambetter from Arizona Complete Health CMS-0057-F prior authorization requirements for exchange plans (list dated December 31, 2025). Verify with the payer before scheduling.

Does AmeriHealth Caritas require prior authorization for J1427?

AmeriHealth Caritas lists J1427 on AmeriHealth Caritas Louisiana prior authorization service list for medicaid managed plans. Verify with the payer before scheduling.

Does Anthem BCBS require prior authorization for J1427?

Anthem BCBS lists J1427 on Anthem Local PPO Precertification/Prior Authorization List (California | Anthem Blue Cross | Commercial) for commercial plans (list dated November 1, 2026). Verify with the payer before scheduling.

Does Arizona Complete Health require prior authorization for J1427?

Arizona Complete Health lists J1427 on Arizona Complete Health CMS-0057-F prior authorization requirements for medicaid managed plans (list dated December 31, 2025). Verify with the payer before scheduling.

What insurance policy changes affect HCPCS J1427?

There are 10 tracked policy changes affecting HCPCS J1427, including updates from Florida Blue, Mississippi Medicaid (DOM), Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for HCPCS J1427?

Payers that have issued tracked updates for HCPCS J1427 include: Florida Blue, Mississippi Medicaid (DOM), Aetna, Michigan Medicaid - MDHHS, Blue Cross & Blue Shield of Mississippi, Colorado Medicaid.

How do I get notified when HCPCS J1427 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to HCPCS J1427. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for HCPCS J1427?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

See every payer rule for J1427

Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for J1427 in one place.

See every payer rule

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

New Drug Waste Reduction Guideline

Notice of Change for Physician-Administered Drug Program

Physician Administered Drugs: Prior Authorization Requirements

Lyme Disease and other Tick-Borne Diseases (CPB 0215, reviewed 2026-07-21)

Gene-Based Therapy for Duchenne Muscular Dystrophy (DMD) (CPB 0911, reviewed 2026-08-05)

MSA 21-18

State and School Employees' Health Insurance Plan - Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy (DMD)

Health First Colorado (Colorado's Medicaid Program) News and Updates (B2200487 - 12/2022)

Health First Colorado (Colorado's Medicaid Program) News and Updates (B2300488 - 01/2023)

Prior authorization required

Prior authorization required

Prior authorization required

Does Aetna require prior authorization for J1427?

Does Ambetter require prior authorization for J1427?

Does AmeriHealth Caritas require prior authorization for J1427?

Does Anthem BCBS require prior authorization for J1427?

Does Arizona Complete Health require prior authorization for J1427?

What insurance policy changes affect HCPCS J1427?

Which payers have updated policy for HCPCS J1427?

How do I get notified when HCPCS J1427 policy changes?

Why do payers change policies for HCPCS J1427?